Row SystemWave Shape Decorative svg added to top
Resource Library Cell-Free Antibodies Predict CHO Binding Kinetics
Cell-Free Antibodies Predict CHO Binding Kinetics

Cell-Free Antibodies Predict CHO Binding Kinetics

Modern antibody discovery has an asymmetry problem: generative design proposes thousands of sequences in silico, but wet-lab validation stays slow, expensive, and capacity-limited. At the first gate, the question is narrow — does this candidate express, and does it bind the target? You don't need full mammalian biology to answer it.

This white paper presents a head-to-head validation dataset showing that an engineered E. coli cell-free protein synthesis (CFPS) system produces full-length IgG1 antibodies whose early binding readouts closely track CHO-made controls. The goal isn't to replace CHO — it's to establish CFPS as a reliable triage step before every candidate is committed to mammalian expression, so teams can shrink the candidate pool and focus on sequences backed by experimental evidence.

In this white paper, you'll discover:

  • Confirmed full-length IgG1 assembly: How reduced and non-reduced SDS-PAGE verify correct heavy-chain / light-chain pairing and fully assembled, disulfide-bonded IgG1.
  • Kinetics that track CHO: How SPR-derived KD, kon, and koff values from CFPS-made trastuzumab, cetuximab, and nivolumab align closely with CHO controls (e.g. trastuzumab KD of 1.18 nM cell-free vs 1.24 nM CHO), alongside overlapping ELISA dose-response curves with EC₅₀ values in the same range.
  • The glycosylation question, resolved: Why aglycosylated CFPS-made IgG still generate binding profiles comparable to glycosylated CHO material, confirming that Fc glycosylation is critical for later-stage biology (ADCC, CDC, developability) but not always required for early target-binding screening.
  • A clear decision framework: When to run CFPS first versus CHO first, so you spend mammalian capacity only on candidates that already carry experimental evidence.

Why It Matters

The wet lab shouldn't be the slow checkpoint at the end of a computational design round. By shifting early hit validation to an engineered E. coli cell-free system that yields near-identical binding kinetics to CHO-made controls, discovery teams can screen broader libraries earlier, eliminate non-binders sooner, and reserve costly mammalian workflows strictly for their strongest, confirmed leads.

Contributors

Chris Icke - Senior Scientist Workflow Development in Protein Science
Ania Boczkaj - Senior Scientist, Antibodies in Protein Science
Sumit Kalsi - Associate Director Product Research in DMF Research
Andreas Waeber - Senior Software Developer in Workflow Software
Raman Pandey - Principal Scientist in Protein Science
Mozhdeh Khajvand - Senior Workflow Engineer in Integration
Ruben Tomás - Sr Product Marketing Manager

Download: Cell-Free Antibodies Predict CHO Binding Kinetics